Trials / Withdrawn
WithdrawnNCT01599429
Study of the Predictive Marker FLT in Patients Suffering From AML
Use of FLT-TEP Scan as Predictive Marker and Early Prognostic in Patients Suffering From AML Treated by Chemotherapy
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Positron emission tomography uses various radioactive tracers to measure the metabolic activity in a none-invasive way, and specially to follow the activity of the disease during the treatments. Among those new tracers, fluorothymidine (18F-FLT) arouses a lot of interest. This new tool would allow to image and follow time wise acute myeloid leukemia (AML). The investigators want, with the (18F-FLT), to characterise the aggressivity of the tumors and the prognostic before and after chemotherapy treatment. The aim of this study is to be able to identify earlier the responders, because if they are detected sooner, these patients will benefit from more aggressive treatments.
Conditions
Timeline
- Start date
- 2011-10-31
- Primary completion
- 2017-10-31
- Completion
- 2017-12-31
- First posted
- 2012-05-16
- Last updated
- 2021-04-14
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT01599429. Inclusion in this directory is not an endorsement.